Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Retained Earnings (2021 - 2025)

Historic Retained Earnings for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to -$253.3 million.

  • ARS Pharmaceuticals' Retained Earnings fell 4620.21% to -$253.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$253.3 million, marking a year-over-year decrease of 4620.21%. This contributed to the annual value of -$123.3 million for FY2024, which is 609.13% up from last year.
  • ARS Pharmaceuticals' Retained Earnings amounted to -$253.3 million in Q3 2025, which was down 4620.21% from -$202.1 million recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Retained Earnings registered a high of -$42.3 million during Q4 2021, and its lowest value of -$253.3 million during Q3 2025.
  • Over the past 5 years, ARS Pharmaceuticals' median Retained Earnings value was -$141.6 million (recorded in 2024), while the average stood at -$152.0 million.
  • As far as peak fluctuations go, ARS Pharmaceuticals' Retained Earnings crashed by 8238.86% in 2022, and later skyrocketed by 5641.35% in 2023.
  • Over the past 5 years, ARS Pharmaceuticals' Retained Earnings (Quarter) stood at -$42.3 million in 2021, then tumbled by 82.08% to -$76.9 million in 2022, then crashed by 70.66% to -$131.3 million in 2023, then grew by 6.09% to -$123.3 million in 2024, then crashed by 105.41% to -$253.3 million in 2025.
  • Its last three reported values are -$253.3 million in Q3 2025, -$202.1 million for Q2 2025, and -$157.2 million during Q1 2025.